A STRATEGY TO TREAT THE BREAST CANCER THROUGH INHIBITING THE OVER EXPRESSION OF PROTEIN ESTROGEN VIA SCHIFF BASE FUSED COUMARIN: AN IN-SILICO BASED SYNTHETIC APPROACH

Coumarin and its analogs have a wide range of attention in the treatment of hormone-dependent breast cancer by blocking the formation of estrogen through the inhibition of estrogen receptor. However, the Schiff bases are an important class of compounds with structural similarities of natural biological substances and also due to their presence of imine (-N=CH-), which have an impact on a biological system. Considering the above all facts, the present research work is aimed to design the series of building blocks of coumarin Schiff base moiety as target candidates for estrogen receptor. The designed molecules ensured their reliability through the in-silico drug designing model and subjected to a preliminary study by screening their violation of Lipinski rule of five, if any, predicted for their ADMET profile study by using online available tools. Later an attempt was made to synthesize the proposed compounds, and structural elucidation was done by IR, NMR, and Mass spectroscopy. Besides to this, an in-vitro cytotoxicity study by using human breast cancer cell lines also carried out to evaluate the anti-tumor potency of the synthesized coumarin conjugates as a promising candidate for treating the breast cancer. The results obtained from these tools show there is no Lipinski rule violation, and no toxicity is predicted for these synthesized compounds. Thus, the designed coumarin Schiff base derivatives might serve as the best leads for treating the breast cancer, which is additionally confirmed by performing their docking study via Accelrys discovery studio for inhibiting the production of estrogen.